Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 2/2013

01.04.2013 | Review

The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy

verfasst von: Mun Hui, Aurélie Cazet, Radhika Nair, D Neil Watkins, Sandra A O'Toole, Alexander Swarbrick

Erschienen in: Breast Cancer Research | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Despite the progress achieved in breast cancer screening and therapeutic innovations, the basal-like subtype of breast cancer (BLBC) still represents a particular clinical challenge. In order to make an impact on survival in this type of aggressive breast cancer, new targeted therapeutic agents are urgently needed. Aberrant activation of the Hedgehog (Hh) signalling pathway has been unambiguously tied to cancer development and progression in a variety of solid malignancies, and the recent approval of vismodegib, an orally bioavailable small-molecule inhibitor of Smoothened, validates Hh signalling as a valuable therapeutic target. A number of recent publications have highlighted a role for Hh signalling in breast cancer models and clinical specimens. Interestingly, Hh ligand overexpression is associated with the BLBC phenotype and a poor outcome in terms of metastasis and breast cancer-related death. In this review, we provide a comprehensive overview of the canonical Hh signalling pathway in mammals, highlight its roles in mammary gland development and breast carcinogenesis and discuss its potential therapeutic value in BLBC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516.CrossRefPubMed
2.
3.
Varjosalo M, Taipale J: Hedgehog: functions and mechanisms. Genes Dev. 2008, 22: 2454-2472. 10.1101/gad.1693608.CrossRefPubMed
4.
Mullor JL, Sanchez P, Ruiz i Altaba A: Pathways and consequences: Hedgehog signaling in human disease. Trends Cell Biol. 2002, 12: 562-569. 10.1016/S0962-8924(02)02405-4.CrossRefPubMed
5.
6.
Hooper JE, Scott MP: Communicating with Hedgehogs. Nat Rev Mol Cell Biol. 2005, 6: 306-317. 10.1038/nrm1622.CrossRefPubMed
7.
Porter JA, von Kessler DP, Ekker SC, Young KE, Lee JJ, Moses K, Beachy PA: The product of hedgehog autoproteolytic cleavage active in local and long-range signalling. Nature. 1995, 374: 363-366. 10.1038/374363a0.CrossRefPubMed
8.
Burke R, Nellen D, Bellotto M, Hafen E, Senti KA, Dickson BJ, Basler K: Dispatched, a novel sterol-sensing domain protein dedicated to the release of cholesterol-modified hedgehog from signaling cells. Cell. 1999, 99: 803-815. 10.1016/S0092-8674(00)81677-3.CrossRefPubMed
9.
Hahn H, Christiansen J, Wicking C, Zaphiropoulos PG, Chidambaram A, Gerrard B, Vorechovsky I, Bale AE, Toftgard R, Dean M, Wainwright B: A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities. J Biol Chem. 1996, 271: 12125-12128. 10.1074/jbc.271.21.12125.CrossRefPubMed
10.
Beachy PA, Hymowitz SG, Lazarus RA, Leahy DJ, Siebold C: Interactions between Hedgehog proteins and their binding partners come into view. Genes Dev. 2010, 24: 2001-2012. 10.1101/gad.1951710.CrossRefPubMedPubMedCentral
11.
McLellan JS, Zheng X, Hauk G, Ghirlando R, Beachy PA, Leahy DJ: The mode of Hedgehog binding to Ihog homologues is not conserved across different phyla. Nature. 2008, 455: 979-983. 10.1038/nature07358.CrossRefPubMedPubMedCentral
12.
Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J: Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell. 2008, 14: 700-711. 10.1016/j.devcel.2008.03.006.CrossRefPubMed
13.
Alcedo J, Ayzenzon M, Von Ohlen T, Noll M, Hooper JE: The Drosophila smoothened gene encodes a seven-pass membrane protein, a putative receptor for the hedgehog signal. Cell. 1996, 86: 221-232. 10.1016/S0092-8674(00)80094-X.CrossRefPubMed
14.
Stecca B, Ruiz IAA: Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol. 2010, 2: 84-95. 10.1093/jmcb/mjp052.CrossRefPubMedPubMedCentral
15.
Harris LG, Samant RS, Shevde LA: Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. Mol Cancer Res. 2011, 9: 1165-1174. 10.1158/1541-7786.MCR-11-0175.CrossRefPubMedPubMedCentral
16.
Huangfu D, Liu A, Rakeman AS, Murcia NS, Niswander L, Anderson KV: Hedgehog signalling in the mouse requires intraflagellar transport proteins. Nature. 2003, 426: 83-87. 10.1038/nature02061.CrossRefPubMed
17.
Garcia-Zaragoza E, Perez-Tavarez R, Ballester A, Lafarga V, Jimenez-Reinoso A, Ramirez A, Murillas R, Gallego MI: Intraepithelial paracrine Hedgehog signaling induces the expansion of ciliated cells that express diverse progenitor cell markers in the basal epithelium of the mouse mammary gland. Dev Biol. 2012, 372: 28-44. 10.1016/j.ydbio.2012.09.005.CrossRefPubMed
18.
Wong SY, Seol AD, So PL, Ermilov AN, Bichakjian CK, Epstein EH, Dlugosz AA, Reiter JF: Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis. Nat Med. 2009, 15: 1055-1061. 10.1038/nm.2011.CrossRefPubMedPubMedCentral
19.
Han YG, Kim HJ, Dlugosz AA, Ellison DW, Gilbertson RJ, Alvarez-Buylla A: Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med. 2009, 15: 1062-1065. 10.1038/nm.2020.CrossRefPubMedPubMedCentral
20.
Jenkins D: Hedgehog signalling: emerging evidence for non-canonical pathways. Cell Signal. 2009, 21: 1023-1034. 10.1016/j.cellsig.2009.01.033.CrossRefPubMed
21.
Mille F, Thibert C, Fombonne J, Rama N, Guix C, Hayashi H, Corset V, Reed JC, Mehlen P: The Patched dependence receptor triggers apoptosis through a DRAL-caspase-9 complex. Nat Cell Biol. 2009, 11: 739-746. 10.1038/ncb1880.CrossRefPubMedPubMedCentral
22.
Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, Matrisian LM, Mundy GR, Sterling JA: TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res. 2011, 71: 822-831. 10.1158/0008-5472.CAN-10-2993.CrossRefPubMed
23.
Watson CJ, Khaled WT: Mammary development in the embryo and adult: a journey of morphogenesis and commitment. Development. 2008, 135: 995-1003. 10.1242/dev.005439.CrossRefPubMed
24.
Michno K, Boras-Granic K, Mill P, Hui CC, Hamel PA: Shh expression is required for embryonic hair follicle but not mammary gland development. Dev Biol. 2003, 264: 153-165. 10.1016/S0012-1606(03)00401-9.CrossRefPubMed
25.
Kouros-Mehr H, Werb Z: Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev Dyn. 2006, 235: 3404-3412. 10.1002/dvdy.20978.CrossRefPubMedPubMedCentral
26.
Hatsell SJ, Cowin P: Gli3-mediated repression of Hedgehog targets is required for normal mammary development. Development. 2006, 133: 3661-3670. 10.1242/dev.02542.CrossRefPubMed
27.
Lewis MT, Ross S, Strickland PA, Sugnet CW, Jimenez E, Hui C, Daniel CW: The Gli2 transcription factor is required for normal mouse mammary gland development. Dev Biol. 2001, 238: 133-144. 10.1006/dbio.2001.0410.CrossRefPubMed
28.
Gritli-Linde A, Hallberg K, Harfe BD, Reyahi A, Kannius-Janson M, Nilsson J, Cobourne MT, Sharpe PT, McMahon AP, Linde A: Abnormal hair development and apparent follicular transformation to mammary gland in the absence of hedgehog signaling. Dev Cell. 2007, 12: 99-112. 10.1016/j.devcel.2006.12.006.CrossRefPubMedPubMedCentral
29.
Moraes RC, Zhang X, Harrington N, Fung JY, Wu MF, Hilsenbeck SG, Allred DC, Lewis MT: Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development. 2007, 134: 1231-1242. 10.1242/dev.02797.CrossRefPubMed
30.
Lewis MT, Ross S, Strickland PA, Sugnet CW, Jimenez E, Scott MP, Daniel CW: Defects in mouse mammary gland development caused by conditional haploinsufficiency of Patched-1. Development. 1999, 126: 5181-5193.PubMed
31.
Moraes RC, Chang H, Harrington N, Landua JD, Prigge JT, Lane TF, Wainwright BJ, Hamel PA, Lewis MT: Ptch1 is required locally for mammary gland morphogenesis and systemically for ductal elongation. Development. 2009, 136: 1423-1432. 10.1242/dev.023994.CrossRefPubMedPubMedCentral
32.
Fiaschi M, Rozell B, Bergstrom A, Toftgard R, Kleman MI: Targeted expression of GLI1 in the mammary gland disrupts pregnancy-induced maturation and causes lactation failure. J Biol Chem. 2007, 282: 36090-36101. 10.1074/jbc.M704280200.CrossRefPubMed
33.
McDermott KM, Liu BY, Tlsty TD, Pazour GJ: Primary cilia regulate branching morphogenesis during mammary gland development. Curr Biol. 2010, 20: 731-737. 10.1016/j.cub.2010.02.048.CrossRefPubMedPubMedCentral
34.
Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE: Generation of a functional mammary gland from a single stem cell. Nature. 2006, 439: 84-88. 10.1038/nature04372.CrossRefPubMed
35.
Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ: Purification and unique properties of mammary epithelial stem cells. Nature. 2006, 439: 993-997.PubMed
36.
Blanpain C: Tracing the cellular origin of cancer. Nat Cell Biol. 2012, 15: 126-134.CrossRef
37.
Van Keymeulen A, Rocha AS, Ousset M, Beck B, Bouvencourt G, Rock J, Sharma N, Dekoninck S, Blanpain C: Distinct stem cells contribute to mammary gland development and maintenance. Nature. 2011, 479: 189-193. 10.1038/nature10573.CrossRefPubMed
38.
Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, Reis-Filho JS, Smalley MJ: BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell. 2010, 7: 403-417. 10.1016/j.stem.2010.07.010.CrossRefPubMed
39.
Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ; kConFab, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009, 15: 907-913. 10.1038/nm.2000.CrossRefPubMed
40.
Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P, Wicha MS: Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006, 66: 6063-6071. 10.1158/0008-5472.CAN-06-0054.CrossRefPubMedPubMedCentral
41.
Fiaschi M, Rozell B, Bergstrom A, Toftgard R: Development of mammary tumors by conditional expression of GLI1. Cancer Res. 2009, 69: 4810-4817. 10.1158/0008-5472.CAN-08-3938.CrossRefPubMedPubMedCentral
42.
Li N, Singh S, Cherukuri P, Li H, Yuan Z, Ellisen LW, Wang B, Robbins D, DiRenzo J: Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells. Stem Cells. 2008, 26: 1253-1264. 10.1634/stemcells.2007-0691.CrossRefPubMedPubMedCentral
43.
Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, VanArsdale T, Beachy PA, Reya T: Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009, 458: 776-779. 10.1038/nature07737.CrossRefPubMedPubMedCentral
44.
Santini R, Vinci MC, Penachioni JY, Montagnani V, Olivito B, Gattai R, Pimpinelli N, Gerlini G, Borgognoni L, Stecca B: Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells. 2012, 30: 1808-1818. 10.1002/stem.1160.CrossRefPubMed
45.
Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, Bernard K, Conklin JF, Szczepny A, Yuan J, Guo R, Ospina B, Falzon J, Bennett S, Brown TJ, Markovic A, Devereux WL, Ocasio CA, Chen JK, Stearns T, Thomas RK, Dorsch M, Buonamici S, Watkins DN, Peacock CD, Sage J: A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med. 2011, 17: 1504-1508. 10.1038/nm.2473.CrossRefPubMedPubMedCentral
46.
Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A: Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med. 2009, 1: 338-351. 10.1002/emmm.200900039.CrossRefPubMedPubMedCentral
47.
Kinzler KW, Bigner SH, Bigner DD, Trent JM, Law ML, O'Brien SJ, Wong AJ, Vogelstein B: Identification of an amplified, highly expressed gene in a human glioma. Science. 1987, 236: 70-73. 10.1126/science.3563490.CrossRefPubMed
48.
Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, Veelken H, Engelhardt M, Mertelsmann R, Kelleher JF, Schultz P, Warmuth M: Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med. 2007, 13: 944-951. 10.1038/nm1614.CrossRefPubMed
49.
O'Toole SA, Swarbrick A, Sutherland RL: The Hedgehog signalling pathway as a therapeutic target in early breast cancer development. Expert Opin Ther Targets. 2009, 13: 1095-1103. 10.1517/14728220903130612.CrossRefPubMed
50.
Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH, Scott MP: Basal cell carcinomas in mice overexpressing sonic hedgehog. Science. 1997, 276: 817-821. 10.1126/science.276.5313.817.CrossRefPubMed
51.
Xie J, Johnson RL, Zhang X, Bare JW, Waldman FM, Cogen PH, Menon AG, Warren RS, Chen LC, Scott MP, Epstein EH: Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res. 1997, 57: 2369-2372.PubMed
52.
Vorechovsky I, Benediktsson KP, Toftgard R: The patched/hedgehog/smoothened signalling pathway in human breast cancer: no evidence for H133Y SHH, PTCH and SMO mutations. Eur J Cancer. 1999, 35: 711-713. 10.1016/S0959-8049(99)00017-9.CrossRefPubMed
53.
Naylor TL, Greshock J, Wang Y, Colligon T, Yu QC, Clemmer V, Zaks TZ, Weber BL: High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res. 2005, 7: R1186-1198. 10.1186/bcr1356.CrossRefPubMedPubMedCentral
54.
Nessling M, Richter K, Schwaenen C, Roerig P, Wrobel G, Wessendorf S, Fritz B, Bentz M, Sinn HP, Radlwimmer B, Lichter P: Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res. 2005, 65: 439-447.PubMed
55.
Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, Lin L, et al: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010, 464: 999-1005. 10.1038/nature08989.CrossRefPubMedPubMedCentral
56.
Kubo M, Nakamura M, Tasaki A, Yamanaka N, Nakashima H, Nomura M, Kuroki S, Katano M: Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res. 2004, 64: 6071-6074. 10.1158/0008-5472.CAN-04-0416.CrossRefPubMed
57.
O'Toole SA, Machalek DA, Shearer RF, Millar EK, Nair R, Schofield P, McLeod D, Cooper CL, McNeil CM, McFarland A, Nguyen A, Ormandy CJ, Qiu MR, Rabinovich B, Martelotto LG, Vu D, Hannigan GE, Musgrove EA, Christ D, Sutherland RL, Watkins DN, Swarbrick A: Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res. 2011, 71: 4002-4014. 10.1158/0008-5472.CAN-10-3738.CrossRefPubMed
58.
Wolf I, Bose S, Desmond JC, Lin BT, Williamson EA, Karlan BY, Koeffler HP: Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer. Breast Cancer Res Treatment. 2007, 105: 139-155. 10.1007/s10549-006-9440-4.CrossRef
59.
Cui W, Wang LH, Wen YY, Song M, Li BL, Chen XL, Xu M, An SX, Zhao J, Lu YY, Mi XY, Wang EH: Expression and regulation mechanisms of Sonic Hedgehog in breast cancer. Cancer Sci. 2010, 101: 927-933. 10.1111/j.1349-7006.2010.01495.x.CrossRefPubMed
60.
ten Haaf A, Franken L, Heymann C, von Serenyi S, Cornelissen C, de Hoon JP, Veeck J, Luscher B, Knuchel R, Dahl E: Paradox of sonic hedgehog (SHH) transcriptional regulation: Alternative transcription initiation overrides the effect of downstream promoter DNA methylation. Epigenetics. 2011, 6: 465-477. 10.4161/epi.6.4.14952.CrossRefPubMed
61.
Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB: Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res. 2008, 68: 7795-7802. 10.1158/0008-5472.CAN-08-1078.CrossRefPubMedPubMedCentral
62.
Caserta TM, Kommagani R, Yuan Z, Robbins DJ, Mercer CA, Kadakia MP: p63 overexpression induces the expression of Sonic Hedgehog. Mol Cancer Res. 2006, 4: 759-768. 10.1158/1541-7786.MCR-05-0149.CrossRefPubMed
63.
Xuan Y, Lin Z: Expression of Indian Hedgehog signaling molecules in breast cancer. J Cancer Res Clin Oncol. 2009, 135: 235-240. 10.1007/s00432-008-0451-x.CrossRefPubMed
64.
Souzaki M, Kubo M, Kai M, Kameda C, Tanaka H, Taguchi T, Tanaka M, Onishi H, Katano M: Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer. Cancer Sci. 2011, 102: 373-381. 10.1111/j.1349-7006.2010.01779.x.CrossRefPubMed
65.
Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, Majumder S: Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res. 2012, 72: 5048-5059. 10.1158/0008-5472.CAN-12-1248.CrossRefPubMed
66.
Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, Beachy PA: Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003, 425: 846-851. 10.1038/nature01972.CrossRefPubMed
67.
Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA: Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004, 431: 707-712. 10.1038/nature02962.CrossRefPubMed
68.
Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, Beermann F, Ruiz IAA: Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA. 2007, 104: 5895-5900. 10.1073/pnas.0700776104.CrossRefPubMedPubMedCentral
69.
Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, Marshall D, Fu L, Januario T, Kallop D, Nannini-Pepe M, Kotkow K, Marsters JC, Rubin LL, de Sauvage FJ: A paracrine requirement for hedgehog signalling in cancer. Nature. 2008, 455: 406-410. 10.1038/nature07275.CrossRefPubMed
70.
Chen W, Tang T, Eastham-Anderson J, Dunlap D, Alicke B, Nannini M, Gould S, Yauch R, Modrusan Z, DuPree KJ, Darbonne WC, Plowman G, de Sauvage FJ, Callahan CA: Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. Proc Natl Acad Sci USA. 2011, 108: 9589-9594. 10.1073/pnas.1017945108.CrossRefPubMedPubMedCentral
71.
Tian H, Callahan CA, DuPree KJ, Darbonne WC, Ahn CP, Scales SJ, de Sauvage FJ: Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci USA. 2009, 106: 4254-4259. 10.1073/pnas.0813203106.CrossRefPubMedPubMedCentral
72.
Visbal AP, LaMarca HL, Villanueva H, Li Y, Rosen JM, Lewis MT: Altered differentiation and paracrine stimulation of mammary epithelial cell proliferation by conditionally activated Smoothened. Dev Biol. 2011, 352: 116-127. 10.1016/j.ydbio.2011.01.025.CrossRefPubMedPubMedCentral
73.
Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther. 2006, 5: 674-683. 10.4161/cbt.5.6.2906.CrossRefPubMedPubMedCentral
74.
DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL: Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011, 17: 1514-1520. 10.1038/nm.2454.CrossRefPubMedPubMedCentral
75.
Harris LG, Pannell LK, Singh S, Samant RS, Shevde LA: Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61. Oncogene. 2012, 31: 3370-3380. 10.1038/onc.2011.496.CrossRefPubMed
76.
Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 2009, 139: 871-890. 10.1016/j.cell.2009.11.007.CrossRefPubMed
77.
Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, Nieto MA: Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene. 2002, 21: 3241-3246. 10.1038/sj.onc.1205416.CrossRefPubMed
78.
Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N, Kutok JL, Hartwell K, Richardson AL, Weinberg RA: Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA. 2007, 104: 10069-10074. 10.1073/pnas.0703900104.CrossRefPubMedPubMedCentral
79.
Sterling JA, Oyajobi BO, Grubbs B, Padalecki SS, Munoz SA, Gupta A, Story B, Zhao M, Mundy GR: The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res. 2006, 66: 7548-7553. 10.1158/0008-5472.CAN-06-0452.CrossRefPubMed
80.
Das S, Samant RS, Shevde LA: Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis. J Biol Chem. 2011, 286: 9612-9622. 10.1074/jbc.M110.174920.CrossRefPubMed
81.
Heller E, Hurchla MA, Xiang J, Su X, Chen S, Schneider J, Joeng KS, Vidal M, Goldberg L, Deng H, Hornick MC, Prior JL, Piwnica-Worms D, Long F, Cagan R, Weilbaecher KN: Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res. 2012, 72: 897-907. 10.1158/0008-5472.CAN-11-2681.CrossRefPubMed
82.
Das S, Tucker JA, Khullar S, Samant RS, Shevde LA: Hedgehog signaling in tumor cells facilitates osteoblast-enhanced osteolytic metastases. PloS One. 2012, 7: e34374-10.1371/journal.pone.0034374.CrossRefPubMedPubMedCentral
83.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717.
84.
Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010, 28: 3271-3277. 10.1200/JCO.2009.25.9820.CrossRefPubMed
85.
Cooper MK, Porter JA, Young KE, Beachy PA: Teratogen-mediated inhibition of target tissue response to Shh signaling. Science. 1998, 280: 1603-1607. 10.1126/science.280.5369.1603.CrossRefPubMed
86.
Lipinski RJ, Hutson PR, Hannam PW, Nydza RJ, Washington IM, Moore RW, Girdaukas GG, Peterson RE, Bushman W: Dose-and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouse. Toxicol Sci. 2008, 104: 189-197. 10.1093/toxsci/kfn076.CrossRefPubMedPubMedCentral
87.
88.
Dlugosz A, Agrawal S, Kirkpatrick P: Vismodegib. Nat Rev Drug Discovery. 2012, 11: 437-438. 10.1038/nrd3753.CrossRefPubMed
89.
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012, 366: 2171-2179. 10.1056/NEJMoa1113713.CrossRefPubMed
90.
LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von HoffDD: Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011, 17: 2502-2511. 10.1158/1078-0432.CCR-10-2745.CrossRefPubMed
91.
Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009, 361: 1173-1178. 10.1056/NEJMoa0902903.CrossRefPubMed
92.
Dijkgraaf GJ, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, Burdick D, Goldsmith R, Robarge K, Sutherlin D, Scales SJ, Gould SE, Yauch RL, de Sauvage FJ: Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011, 71: 435-444. 10.1158/0008-5472.CAN-10-2876.CrossRefPubMed
93.
Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA: Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer cell. 2010, 17: 388-399. 10.1016/j.ccr.2010.02.027.CrossRefPubMedPubMedCentral
94.
Lauth M, Bergstrom A, Shimokawa T, Toftgard R: Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA. 2007, 104: 8455-8460. 10.1073/pnas.0609699104.CrossRefPubMedPubMedCentral
95.
Hyman JM, Firestone AJ, Heine VM, Zhao Y, Ocasio CA, Han K, Sun M, Rack PG, Sinha S, Wu JJ, Solow-Cordero DE, Jiang J, Rowitch DH, Chen JK: Smallmolecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci USA. 2009, 106: 14132-14137. 10.1073/pnas.0907134106.CrossRefPubMedPubMedCentral
96.
Kim J, Lee JJ, Kim J, Gardner D, Beachy PA: Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA. 2010, 107: 13432-13437. 10.1073/pnas.1006822107.CrossRefPubMedPubMedCentral
97.
Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O, Macdonald TJ, Albanese C, Toretsky JA, Uren A: Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 2011, 121: 148-160. 10.1172/JCI42874.CrossRefPubMed
98.
Stanton BZ, Peng LF, Maloof N, Nakai K, Wang X, Duffner JL, Taveras KM, Hyman JM, Lee SW, Koehler AN, Chen JK, Fox JL, Mandinova A, Schreiber SL: A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol. 2009, 5: 154-156. 10.1038/nchembio.142.CrossRefPubMedPubMedCentral
99.
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009, 324: 1457-1461. 10.1126/science.1171362.CrossRefPubMedPubMedCentral
100.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed
101.
Nolan-Stevaux O, Lau J, Truitt ML, Chu GC, Hebrok M, Fernandez-Zapico ME, Hanahan D: GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009, 23: 24-36. 10.1101/gad.1753809.CrossRefPubMedPubMedCentral
102.
Bissell MJ, Hines WC: Why don't we get more cancer? A proposed role of the microenviron ment in restraining cancer progression. Nat Med. 2011, 17: 320-329. 10.1038/nm.2328.CrossRefPubMedPubMedCentral
Metadaten
Titel
The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy
verfasst von
Mun Hui
Aurélie Cazet
Radhika Nair
D Neil Watkins
Sandra A O'Toole
Alexander Swarbrick
Publikationsdatum
01.04.2013
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 2/2013
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3401

Weitere Artikel der Ausgabe 2/2013

Breast Cancer Research 2/2013 Zur Ausgabe

Research article

Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II

Research article

Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

Research article

Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer

Research article

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer

Research article

HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease

Research article

Vaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise